Interferon-induced upregulation and cytoplasmic localization of Myc- interacting protein Nmi

Journal of Interferon and Cytokine Research

Volumn 18, Issue 9, 1998, Pages 767-771

  Lebrun, Stewart J ^a   Shpall, Rebecca L ^a   Naumovski, Louie ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON;

ANIMAL CELL; ARTICLE; DNA BINDING; GENETIC TRANSCRIPTION; GROWTH REGULATION; IMMUNOPRECIPITATION; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; RECEPTOR UPREGULATION; TARGET CELL;

ANIMALIA;

EID: 0031716567     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.1998.18.767     Document Type: Article

References (15)

1. DIANZANI, F., and ANTONELLI, G. (1997). In: Clinical Applications of the Interferons. R. Stuart-Harris and R. Penny (eds.). London: Chapman & Hall, pp. 19-31.
2. DARNELL, J.E., KERR, I.M., and STARK, G.R. (1994). Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264, 1415-1421.
3. MIN, W., GHOSH, S., and LENGYEL, P. (1996). The interferon-inducible p202 protein as a modulator of transcription: inhibition of NF-κB, c-Fos and c-Jun activities. Mol Cell Biol. 16, 359-368.
4. WANG, X., JOHANSEN, L.M., TAE, H.-J., and TAPAROWSKY, E.J. (1996). IFP 35 forms complexes with B-ATF, a member of the API family of transcription factors. Biochem. Biophys. Res. Commun. 229, 316-322.
5. BANGE, F.-C., VOGEL, U., FLOHR, T., KIEKENBECK, M., DENECKE, B., and BOTTGER, E.C. (1994). IFP 35 is an interferon-induced leucine zipper protein that undergoes interferon-regulated cellular redistribution. J. Biol. Chem. 269, 1091-1098.
6. BAO, J., and ZERVOS, A. (1996). Isolation and characterization of a Nmi, a novel partner of Myc proteins. Oncogene 12, 2171-2176.
7. NAUMOVSKI, L., and CLEARY, M.L. (1994). Bcl2 inhibits apoptosis associated with terminal differentiation of HL-60 myeloid leukemia cells. Blood 83; 2261-2267.
8. NAUMOVSKI, L., and CLEARY, M.L. (1996). The p53-binding protein 53BP2 also interacts with Bcl2 and impedes cell cycle progression at G2M. Mol. Cell. Biol. 16, 3884-3892.
9. YOUSSOUFIAN, H. (1998). Immunoaffinity purification of antibodies against GST fusion proteins. BioTechniques 24, 198-202.
10. HSU, Y.T., WOLTER, K.G., and YOULE, R.J. (1997). Cytosol-to-membrane redistribution of Bax and Bcl-xL during apoptosis. Proc. Natl. Acad. Sci. USA 94, 3668-3672.
11. HEISE, H., DEPENBROCK, H., RASTETTER, J.W., and HANAUSKE, A.R. (1995). Characterization and mutual ligand-induced modulation of epidermal growth factor and interferon-alpha receptors on renal cell carcinoma cell lines. Anti-Cancer Drugs 6, 686-692.
12. BENEZRA, R., DAVIS, R.L., LOCKSHON, D., TURNER, D.L., and WEINTRAUB, H. (1990). The protein Id: a negative regulator of helix-loop-helix DNA binding proteins. Cell 61, 49-59.
13. RON, D., and HABENER, J.F. (1992). CHOP, a novel developmentally regulated nuclear protein that dimerizes with transcription factors C/EBP and LAP and functions as a dominant-negative inhibitor of gene transcription. Genes Dev. 6, 439-453.
14. ALEXANDROVA, N., NIKLINSKI, J., BLISKOVSKY, V., OTTERSON, G.A., BLAKE, M., KAYE, F.J., and ZAJAC-KAYE, M. (1995). The N-terminal domain of c-Myc associates with α-tutulin and microtubules in vivo and in vitro. Mol. Cell. Biol. 15, 5188-5195.
15. ROYDS, J.A., SHARRARD, R.M., WAGNER, B., and POLACARZ, S.V. (1992). Cellular localisation of c-myc product in human colorectal epithelial neoplasia. J. Pathol. 166, 225-233.